Skip to main content

Table 6 Immune-histochemical results and statistical analyses of AR considered as continuous variable: comparisons of both cases vs controls and primary vs metastatic lesions

From: Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers

IHC parameter

Cases vs controls // primary vs metastatic lesions (%)

N

Mean (%)

Median (%)

Range

pValue

AR

Cases

39

14.15

5

0–70

<  0.001

Controls

40

42.05

37.5

0–95

Primary tumor

24

12.70

2.5

0–70

0.270

Brain metastasis

24

9.25

0

0–60

  1. AR Androgen Receptor